Clinical Trial Detail

NCT ID NCT02269670
Title Phase II Study of Everolimus Beyond Progression
Recruitment Active, not recruiting
Gender female
Phase Phase II
Variant Requirements yes
Sponsors Emory University
Indications

Her2-receptor negative breast cancer

Therapies

Tamoxifen

Everolimus

Megestrol acetate

Letrozole

Fulvestrant

Anastrozole

Age Groups: adult senior

Additional content available in CKB BOOST